A Systematic Review and Meta-analysis of the Association Between Implantable Cardioverter-Defibrillator Shocks and Long-term Mortality

Canadian Journal of Cardiology

Volumn 31, Issue 3, 2015, Pages 270-277

  Proietti, Riccardo ^a,b   Labos, Christopher ^a   Davis, Mark ^a   Thanassoulis, George ^a   Santangeli, Pasquale ^c   Russo, Vincenzo ^d   Di Biase, Luigi ^e,f   Roux, Jean Francois ^a,g   Verma, Atul ^a,h   Natale, Andrea ^e,i,j,k   Essebag, Vidal ^a,l  

^a MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^b UNIVERSITY OF MILAN   (Italy)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d MONALDI HOSPITAL   (Italy)

^e TEXAS CARDIAC ARRHYTHMIA INSTITUTE   (United States)

^f ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^g CENTRE HOSPITALIER UNIVERSITAIRE DE SHERBROOKE   (Canada)

^h SOUTHLAKE REGIONAL HEALTH CENTRE   (Canada)

ⁱ CASE WESTERN RESERVE UNIVERSITY   (United States)

^j CALIFORNIA PACIFIC MEDICAL CENTER   (United States)

^k SCRIPPS CLINIC   (United States)

^l HÔPITAL DU SACRÉ COEUR DE MONTRÉAL   (Canada)

more..

Author keywords

[No Author keywords available]

Indexed keywords

EFFECT SIZE; HEART DEATH; HEART VENTRICLE ARRHYTHMIA; HUMAN; IMPLANTABLE CARDIOVERTER DEFIBRILLATOR; INFORMATION RETRIEVAL; META ANALYSIS; MORTALITY; QUALITY CONTROL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK ASSESSMENT; SHOCK; SYSTEMATIC REVIEW; ADVERSE EFFECTS; ARRHYTHMIAS, CARDIAC; HEART FAILURE; RISK FACTOR; SURVIVAL;

ARRHYTHMIAS, CARDIAC; DEFIBRILLATORS, IMPLANTABLE; HEART FAILURE; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS; SURVIVAL ANALYSIS;

EID: 84923927051     PISSN: 0828282X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cjca.2014.11.023     Document Type: Review

References (53)

1. Acomparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. The Antiarrhythmics versus Implantable Defibrillators (AVID) Investigators. NEngl J Med 1997, 337:1576-1583.
2. Buxton A.E., Lee K.L., Fisher J.D., et al. Arandomized study of the prevention of sudden death in patients with coronary artery disease. Multicenter Unsustained Tachycardia Trial Investigators. NEngl J Med 1999, 341:1882-1890.
3. Connolly S.J., Gent M., Roberts R.S., et al. Canadian implantable defibrillator study (CIDS): a randomized trial of the implantable cardioverter-defibrillator against amiodarone. Circulation 2000, 101:1297-1302.
4. Moss A.J., Hall W.J., Cannom D.S., et al. Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. Multicenter Automatic Defibrillator Implantation Trial Investigators. NEngl J Med 1996, 335:1933-1940.
5. Moss A.J., Zareba W., Hall W.J., et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. NEngl J Med 2002, 346:877-883. Multicenter Automatic Defibrillator Implantation Trial II Investigators.
6. Essebag V., Eisenberg M.J. Expanding indications for defibrillators after myocardial infarction: risk stratification and cost effectiveness. Card Electrophysiol Rev 2003, 7:43-48.
7. Moss A.J., Greenberg H., Case R.B., et al. Long-term clinical course of patients after termination of ventricular tachyarrhythmia by an implanted defibrillator. Circulation 2004, 110:3760-3765. Multicenter Automatic Defibrillator Implantation Trial-II Research Group.
8. Poole J.E., Johnson G.W., Hellkamp A.S., et al. Prognostic importance of defibrillator shocks in patients with heart failure. NEngl J Med 2008, 359:1009-1017.
9. Daubert J.P., Zareba W., Cannom D.S., et al. Inappropriate implantable cardioverter-defibrillator shocks in MADIT II: frequency, mechanisms, predictors, and survival impact. JAm Coll Cardiol 2008, 51:1357-1365. MADIT II Investigators.
10. Bhavnani S.P., Kluger J., Coleman C.I., et al. The prognostic impact of shocks for clinical and induced arrhythmias on morbidity and mortality among patients with implantable cardioverter-defibrillators. Heart Rhythm 2010, 7:755-760.
11. Larsen G.K., Evans J., Lambert W.E., Chen Y., Raitt M.H. Shocks burden and increased mortality in implantable cardioverter-defibrillator patients. Heart Rhythm 2011, 8:1881-1886.
12. Powell B.D., Saxon L.A., Boehmer J.P., et al. Survival after shock therapy in implantable cardioverter-defibrillator and cardiac resynchronization therapy-defibrillator recipients according to rhythm shocked. The ALTITUDE survival by rhythm study. JAm Coll Cardiol 2013, 62:1674-1679.
13. Saxon L.A., Hayes D.L., Gilliam F.R., et al. Long-term outcome after ICD and CRT implantation and influence of remote device follow-up: the ALTITUDE survival study. Circulation 2010, 122:2359-2367.
14. Streitner F., Herrmann T., Kuschyk J., et al. Impact of shocks on mortality in patients with ischemic or dilated cardiomyopathy and defibrillators implanted for primary prevention. PLoS One 2013, 8:e63911.
15. van Rees J.B., Borleffs C.J., de Bie M.K., et al. Inappropriate implantable cardioverter-defibrillator shocks: incidence, predictors, and impact on mortality. JAm Coll Cardiol 2011, 57:556-562.
16. Dorian P., Hohnloser S.H., Thorpe K.E., et al. Mechanisms underlying the lack of effect of implantable cardioverter-defibrillator therapy on mortality in high-risk patients with recent myocardial infarction: insights from the Defibrillation in Acute Myocardial Infarction Trial (DINAMIT). Circulation 2010, 122:2645-2652.
17. Hurst T.M., Hinrichs M., Breidenbach C., Katz N., Waldecker B. Detection of myocardial injury during transvenous implantation of automatic cardioverter-defibrillators. JAm Coll Cardiol 1999, 34:402-408.
18. Epstein A.E., Kay G.N., Plumb V.J., Dailey S.M., Anderson P.G. Gross and microscopic pathological changes associated with nonthoracotomy implantable defibrillator leads. Circulation 1998, 98:1517-1524.
19. Tereshchenko L.G., Faddis M.N., Fetics B.J., et al. Transient local injury current in right ventricular electrogram after implantable cardioverter-defibrillator shock predicts heart failure progression. JAm Coll Cardiol 2009, 54:822-828.
20. Xie J., Weil M.H., Sun S., et al. High-energy defibrillation increases the severity of postresuscitation myocardial dysfunction. Circulation 1997, 96:683-688.
21. Ruwald M.H., Zareba W., Jons C., et al. Influence of diabetes mellitus on inappropriate and appropriate implantable cardioverter-defibrillator therapy and mortality in the Multicenter Automatic Defibrillator Implantation Trial-Reduce Inappropriate Therapy (MADIT-RIT) Trial. Circulation 2013, 128:694-701.
22. Tandri H., Griffith L.S., Tang T., et al. Clinical course and long-term follow-up of patients receiving implantable cardioverter-defibrillators. Heart Rhythm 2006, 3:762-768.
23. Mishkin J.D., Saxonhouse S.J., Woo G.W., et al. Appropriate evaluation and treatment of heart failure patients after implantable cardioverter-defibrillator discharge: time to go beyond the initial shock. JAm Coll Cardiol 2009, 54:1993-2000.
24. Hayden J.A., Cote P., Bombardier C. Evaluation of the quality of prognosis studies in systematic reviews. Ann Intern Med 2006, 144:427-437.
25. DerSimonian R., Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986, 7:177-188.
26. Sterne J.A., Sutton A.J., Ioannidis J.P., et al. Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials. BMJ 2011, 343:d4002.
27. Egger M., Davey Smith G., Schneider M., Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997, 315:629-634.
28. Dichtl W., Wolber T., Paoli U., et al. Appropriate therapy but not inappropriate shocks predict survival in implantable cardioverter-defibrillator patients. Clin Cardiol 2011, 34:433-436.
29. Ellenbogen K.A., Levine J.H., Berger R.D., et al. Are implantable cardioverter-defibrillator shocks a surrogate for sudden cardiac death in patients with nonischemic cardiomyopathy?. Circulation 2006, 113:776-782. Defibrillators in Non-Ischemic Cardiomyopathy Treatment Evaluation (DEFINITE) Investigators.
30. Gandhi K., Aronow W.S., Desai H., et al. Incidence of appropriate cardioverter-defibrillator shocks and mortality in patients with implantable cardioverter-defibrillators with ischemic cardiomyopathy versus nonischemic cardiomyopathy at 33-month follow-up. Arch Med Sci 2010, 6:900-903.
31. Moss A.J., Schuger C., Beck C.A., et al. Reduction in inappropriate therapy and mortality through ICD programming. NEngl J Med 2012, 367:2275-2283. MADIT-RIT Trial Investigators.
32. Sweeney M.O., Sherfesee L., DeGroot P.J., Wathen M.S., Wilkoff B.L. Differences in effects of electrical therapy type for ventricular arrhythmias on mortality in implantable cardioverter-defibrillator patients. Heart Rhythm 2010, 7:353-360.
33. Sweeney M.O., Wathen M.S., Volosin K., et al. Appropriate and inappropriate ventricular therapies, quality of life, and mortality among primary and secondary prevention implantable cardioverter-defibrillator patients: results from the Pacing Fast VT REduces Shock ThErapies (PainFREE Rx II) trial. Circulation 2005, 111:2898-2905.
34. Yung D., Birnie D., Dorian P., et al. Survival after implantable cardioverter-defibrillator implantation in the elderly. Circulation 2013, 127:2383-2392.
35. Sood N., Ruwald A.C., Solomon S., et al. Association between myocardial substrate, implantable cardioverter-defibrillator shocks and mortality in MADIT-CRT. Eur Heart J 2014, 35:106-115.
36. Bencardino G., DI Monaco A., Rio T., et al. The association between ICD interventions and mortality is independent of their modality: clinical implications. JCardiovasc Electrophysiol 2014, 25:1363-1367.
37. Ruwald A.C., Schuger C., Moss A.J., et al. Mortality reduction in relation to implantable cardioverter-defibrillator programming in the Multicenter Automatic Defibrillator Implantation Trial-Reduce Inappropriate Therapy (MADIT-RIT). Circ Arrhythm Electrophysiol 2014, 7:785-792.
38. Germano J.J., Reynolds M., Essebag V., Josephson M.E. Frequency and causes of implantable cardioverter-defibrillator therapies: is device therapy proarrhythmic?. Am J Cardiol 2006, 97:1255-1261.
39. Dorian P., Borggrefe M., Al-Khalidi H.R., et al. Placebo-controlled, randomized clinical trial of azimilide for prevention of ventricular tachyarrhythmias in patients with an implantable cardioverter-defibrillator. Circulation 2004, 110:3646-3654. SHock Inhibition Evaluation with azimiLiDe (SHIELD) Investigators.
40. Connolly S.J., Dorian P., Roberts R.S., et al. Comparison of beta-blockers, amiodarone plus beta-blockers, or sotalol for prevention of shocks from implantable cardioverter-defibrillators: the OPTIC Study: a randomized trial. JAMA 2006, 295:165-171. Optimal Pharmacological Therapy in Cardioverter-defibrillator Patients (OPTIC) Investigators.
41. Gasparini M., Proclemer A., Klersy C., et al. Effect of long-detection interval vs standard-detection interval for implantable cardioverter-defibrillators on antitachycardia pacing and shock delivery: the ADVANCE III randomized clinical trial. JAMA 2013, 309:1903-1911.
42. Wilkoff B.L., Williamson B.D., Stern R.S., et al. Strategic programming of detection and therapy parameters in implantable cardioverter-defibrillators reduces shocks in primary prevention patients: results from the PREPARE (Primary Prevention Parameters Evaluation) study. JAm Coll Cardiol 2008, 52:541-550. PREPARE Study Investigators.
43. Kuck K.H., Schaumann A., Eckardt L., et al. Catheter ablation of stable ventricular tachycardia before defibrillator implantation in patients with coronary heart disease (VTACH): a multicentre randomised controlled trial. Lancet 2010, 375:31-40. VTACH study group.
44. Potse M., Essebag V. Guidance for catheter ablation of ventricular arrhythmia. Med Biol Eng Comput 2009, 47:241-243.
45. Ha A.H., Ham I., Nair G.M., et al. Implantable cardioverter-defibrillator shock prevention does not reduce mortality: a systemic review. Heart Rhythm 2012, 9:2068-2074.
46. Tan V.H., Wilton S.B., Kuriachan V., Sumner G.L., Exner D.V. Impact of programming strategies aimed at reducing nonessential implantable cardioverter-defibrillator therapies on mortality: a systematic review and meta-analysis. Circ Arrhyth Electrophysiol 2014, 7:164-170.
47. Kleber A.G., Rudy Y. Basic mechanisms of cardiac impulse propagation and associated arrhythmias. Physiol Rev 2004, 84:431-488.
48. Haqqani H.M., Kalman J.M., Roberts-Thomson K.C., et al. Fundamental differences in electrophysiologic and electroanatomic substrate between ischemic cardiomyopathy patients with and without clinical ventricular tachycardia. JAm Coll Cardiol 2009, 54:166-173.
49. Macintyre C.J., Sapp J.L. Catheter ablation for ventricular tachycardia in structural heart disease. Can J Cardiol 2014, 30:244-246.
50. Alba A.C., Braga J., Gewarges M., et al. Predictors of mortality in patients with an implantable cardiac defibrillator: a systematic review and meta-analysis. Can J Cardiol 2013, 29:1729-1740.
51. Pakhomov A.G., Shevin R., White J.A., et al. Membrane permeabilization and cell damage by ultrashort electric field shocks. Arch Biochem Biophys 2007, 465:109-118.
52. Lee R.C., Zhang D., Hannig J. Biophysical injury mechanisms in electrical shock trauma. Ann Rev Biomed Eng 2000, 2:477-509.
53. Tsuji Y., Hojo M., Voigt N., et al. Ca(2+)-related signaling and protein phosphorylation abnormalities play central roles in a new experimental model of electrical storm. Circulation 2011, 123:2192-2203.